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Abstract: 45 
Muscle satellite cell (SC) regulation is a complex process involving many key signaling 46 
molecules.  Recently, the neurotrophin - brain-derived neurotropic factor (BDNF) has implicated 47 
in SC regulation in animals.  To date, little is known regarding the role of BDNF in human SC 48 
function in vivo. Twenty-nine males (21±0.5y) participated in the study.  Muscle biopsies from 49 
the thigh were obtained prior to a bout of 300 maximal eccentric contractions (PRE), and 6h, 50 
24h, 72h, and 96h of post-exercise. BDNF was not detected in any quiescent (MyoD-/Pax7+) SCs 51 
across the time-course.  BDNF co-localized to 39±5% of proliferating (MyoD+/Pax7+) cells at 52 
PRE, which increased to 84±3% by 96h (P<0.05).  BDNF was only detected in 13±5% of 53 
differentiating (MyoD+/Pax7-) cells at PRE, which increased to 67±4% by 96h (P<0.05).  The 54 
number of Myogenin+ cells increased 95% from PRE (1.6±0.2 cells/100MF) at 24h (3.1±0.3 55 
cells/100MF) and remained elevated until 96h (cells/100MF), p<0.05.  The proportion of 56 
BDNF+/Myogenin+ cells was 26±0.3% at PRE, peaking at 24h (49±3%, p<0.05) and remained 57 
elevated at 96h, (p<0.05).  These data are the first to demonstrate an association between SC 58 
proliferation and differentiation and BDNF expression in humans in vivo, with BDNF co-59 
localization to SCs increasing during the later stages of proliferation and early differentiation. 60 
Novelty:   61 
• BDNF is associated with SC response to muscle injury   62 
• BDNF was not detected in non-activated (quiescent) SCs 63 
• BDNF is associated with late proliferation and early differentiation of SCs in vivo in 64 
humans 65 
 66 
Key Words: Pax7, satellite cells, brain-derived neurotrophic factor, muscle, damage, myogenic 67 
regulatory factors 68 
Introduction: 69 
The myogenic response to a physiological stressor such as muscle damage involves the 70 
coordinated response of several cell types including the tissue-resident stem cells, the muscle 71 
satellite cells (SCs). In adult muscle, SCs represent on a small proportion of the total content of 72 
myonuclei (∼2–5%) yet they possess a remarkable potential for proliferation, capable of 73 
expanding their relative proportion over 30-40% as early as 24h after injury to aid in muscle 74 
repair and hypertrophy (Hawke and Garry 2001, Snijders et al. 2015). Activation, proliferation, 75 
and subsequent differentiation of SCs are controlled by a conserved and unique set of 76 
transcriptional networks aptly named: the myogenic regulatory factors (MRFs). The MRFs are 77 
basic helix-loop-helix (bHLH) transcription factors that form heterodimeric DNA binding 78 
complexes for genes that encode cell-cycle machinery, factors that direct terminal differentiation, 79 
and contractile function (Hawke and Garry 2001, Charge and Rudnicki 2004). The MRFs are 80 
composed of four main transcription factors: Myf5 and MyoD, which are important in 81 
proliferation and early differentiation, and MRF4 and myogenin, which direct terminal 82 
differentiation. The master regulator important in controlling the transcription of the MRFs is the 83 
paired box transcription factor Pax7.  Under the regulation of Pax7 and the MRFs, the process of  84 
SCs progressing through the developmental pathway from a quiescent undifferentiated cell to a 85 
myotube or fusing with a myofiber has been termed the myogenic program (Relaix and Zammit 86 
2012, von et al. 2013, Brack 2014, Oustanina, Hause, and Braun 2004). 87 
The myogenic program is influenced by a host of local growth factors and cytokines such 88 
as androgens, interleukin-6 (IL-6), myostatin (negative regulation) and insulin growth factor-I 89 
(IGF-1) (Snijders et al. 2015) as well as circulating factors and the influence of supporting 90 
tissues such as blood vessels (capillaries) and neural tissue (motor neurons) (Joanisse et al. 2017, 91 
Snijders et al. 2015, Hawke and Garry 2001).  Although the precise mechanisms regulating SCs 92 
in humans are not fully elucidated, a large body of literature has begun to classify the factors 93 
influencing SC regulation.  Importantly, the microenvironment of the SC – the so called ‘SC 94 
niche’ is an area of interest for several lines of research. The niche consists of the myofiber and 95 
the basal lamina between the myofiber and the SC itself, as well as the supporting extracellular 96 
matrix, capillaries, neuromuscular junctions, and surrounding myofibers.  The niche integrates 97 
the local signaling factors as well as the interactions between the SCs and the adjacent cells and 98 
structural elements of its associated fiber as well as systemic influence from the circulation.  In 99 
the last 10 years we have only really begun to understand the influence and importance of the 100 
local environment on SC regulation in vivo.  Data is emerging that demonstrates the importance 101 
of the proximity of the SC to the microcirculation in the muscle to the overall regulation of SC 102 
function (Snijders et al. 2017, Joanisse et al. 2016, Joanisse et al. 2017).  One area of the SC 103 
niche that remains underserved in the current literature is the influence of the motor neuron on 104 
human SC regulation.  There are significant interactions between skeletal muscle and motor 105 
neurons and there are several key molecules involved in these interactions and the neurotrophins 106 
are an emerging area of study.   107 
Neurotrophins are a class of molecules implicated in neuronal plasticity and survival and 108 
are important modulators of neuronal development (Hamburger and Yip 1984, Kablar and 109 
Belliveau 2005).  The neurotrophin: brain-derived neurotrophic factor (BDNF) has been the 110 
basis of intense study and is of particular interest as it has been shown to be produced by skeletal 111 
muscle and motor neurons in animals and humans (Pitts et al. 2006).  Moreover, skeletal muscle 112 
also expresses receptors for BDNF in addition to other neurotrophins (Pitts et al. 2006, Chevrel, 113 
Hohlfeld, and Sendtner 2006).  BDNF is important for neuromuscular health by enhancing motor 114 
neuron survival (Zhang and Poo 2002, Lohof, Ip, and Poo 1993) and a key regulator for normal 115 
embryonic development of the neuromuscular system (Mousavi, Parry, and Jasmin 2004, 116 
Griesbeck et al. 1995).  Data from animal models suggest that BDNF is upregulated in skeletal 117 
muscle following muscle injury and the timing of the peak BDNF expression coincides with SC 118 
proliferation suggesting a potential role for BDNF with SC regulation.  In addition, BDNF has 119 
been shown to be expressed in rat SCs (Mousavi and Jasmin 2006), and more recent data from 120 
Clow and Jasmin (2010), demonstrates BDNF influences SC regulation and may be required for 121 
the early phases of SC and/or myoblast differentiation in a mouse model of regeneration (Clow 122 
and Jasmin 2010).  In mice with a muscle specific knock out of BDNF, myoblasts failed to 123 
transition into differentiation and cultures failed to induce key markers of differentiation such as 124 
myogenin, embryonic myosin heavy chain and p21 compared to controls (Clow and Jasmin 125 
2010).  Although the exact mechanisms remain unknown, data from animal models demonstrate 126 
a role for BDNF in the regulation of normal myogenic differentiation in vivo and in vitro (Clow 127 
and Jasmin 2010, Miura et al. 2012, Mousavi and Jasmin 2006).  More recently, BDNF and its 128 
receptor p75NTR have been localized to human SCs in vivo and in vitro (Colombo et al. 2011, 129 
Colombo et al. 2013).  Data from Colombo and colleagues (2013) demonstrate that the in vitro 130 
silencing of the BDNF gene in human myoblasts interfere with normal myogenesis (Colombo et 131 
al. 2013).  However, the mechanisms responsible for this impairment are not understood.  To 132 
date, there is a paucity of data to describe the role BDNF in human muscle SC regulation in vivo.  133 
Whether BDNF is implicated in normal human muscle SC proliferation or differentiation 134 
remains to be elucidated.  We hypothesize that BDNF would localize to human muscle SC and 135 
that peak elevation in muscle SC BDNF would be associated with MyoD expression and 136 
correspond to the onset of differentiation in response to muscle damage in vivo.                   137 
 138 
Materials and Methods: 139 
Subjects: 140 
Twenty nine healthy young male subjects aged 22 ± 1y, 81 ± 2 kg were recruited for 141 
participation in the study.  Exclusion criteria included the use of supplements and performance 142 
enhancing medications, smoking, diabetes, a history of respiratory disease and/or any major 143 
orthopaedic disability and the use of non-steroidal anti-inflammatory drugs (NSAIDs) and/or 144 
statins, and a history of respiratory disease and/or any major orthopaedic disability.  Woman 145 
were not recruited for the present study due to potential and unknown variations in neurotrophin 146 
expression based on changes associated changes in hormone profile.  However, future work in 147 
this area is necessary to understand the influence of hormone changes on neurotrophins.  All 148 
subjects were informed of the procedures and potential risks associated with the study and gave 149 
their written informed consent to participate.  Subjects were told to refrain from consuming 150 
alcohol, caffeine, anti-inflammatory medications, nutritional supplements and exercising 151 
throughout the time-course of the study.  This study was approved by the Hamilton Health 152 
Sciences Research Ethics Board and conformed to all declarations on the use of human subjects 153 
as research participants.   154 
Muscle Damage Protocol: 155 
To ensure consistency of the stimulus in relation to previous studies from our lab, we employed a 156 
protocol involving maximal isokinetic unilateral muscle lengthening contractions of the 157 
quadriceps femoris performed on a Biodex dynamometer (Biodex-System 3, Biodex Medical 158 
Systems, Inc., USA) at 180 degrees/s-1.  For each subject, the exercised leg was selected 159 
randomly.  Subjects underwent a brief familiarization trial involving 2 sets of 10 submaximal 160 
lengthening contractions.  The experimental protocol has been extensively validated and it is 161 
well documented that this protocol induces a significant level of skeletal muscle damage and is 162 
sufficient to elicit a significant SC response (Toth et al. 2011, McKay et al. 2010, Beaton, 163 
Tarnopolsky, and Phillips 2002).  The protocol is well described elsewhere (Beaton, 164 
Tarnopolsky, and Phillips 2002), briefly, the participants were required to perform 30 sets of 10 165 
maximal muscle lengthening contractions with one minute rest between sets, for a total of 300 166 
lengthening contractions.  Investigators provided verbal encouragement to elicit a maximal effort 167 
from the participants.  These data were recently part of a larger study examining the impact of 168 
capillarization and muscle repair (Nederveen et al. 2018). 169 
Muscle Biopsies: 170 
A total of five percutaneous needle biopsies were obtained from the mid-portion of the vastus 171 
lateralis under local anesthetic (1% lidocaine) using manual suction (Tarnopolsky et al. 2011).  172 
One muscle biopsy was obtained prior to exercise for baseline analysis (PRE).  Other biopsies 173 
were obtained 6h, 24h, 72h, and 96 h post-intervention with the position of the incision 174 
randomized to reduce any effect of the previous biopsy on the outcome variables.   175 
Approximately 50 mg of muscle tissue from each biopsy was mounted in Optimum Cutting 176 
Temperature (OCT) compound and frozen in isopentane cooled in liquid nitrogen for histological 177 
analysis.  The remaining portion was prepared for mRNA analysis.   178 
RNA isolation: 179 
RNA was isolated from 25mg of homogenized muscle samples in 1.0 mL of TRIzol reagent 180 
using the TRIzol/RNeasy method (Invitrogen Corporation, Canada) and Lysing Maxtrix D tubes 181 
(MP Biomedicals, Solon, OH, USA), with the FastPrep-24Tissue and Cell Homogenizer (MP 182 
Biomedicals) for a duration of 40 s at a setting of 6 m/sec (5).  The RNA (aqueous) phase was 183 
purified using the EZNA Total RNA Kit 1 (OmegaBio-Tek, Norcross, GA, USA) as per the 184 
manufacturer’s instructions.   RNA concentration (ng mL−1) and purity (260/280) was 185 
determined with the Nano‐Drop 1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, 186 
MA, USA). 187 
Reverse Transcription (RT): 188 
Individual samples were reverse transcribed in 20 µL reactions using a commercially available 189 
kit (Applied Biosystems High Capacity cDNA Reverse Transcription Kit; Applied Biosystems, 190 
USA) according to the manufacturer’s instructions.  The cDNA synthesis reaction was carried 191 
out on an Eppendorf Mastercycle epgradient thermal cycler (Eppendorf, Canada).   192 
Quantitative Polymerase Chain-Reaction (qPCR): 193 
Individual 25 µL reactions were prepared in 0.2 mL Eppendorf twin.tec PCR plates (Eppendorf, 194 
Canada) and run in duplicate for each time-point as described previously (Nederveen et al. 195 
2018).   Primers for BDNF were (forward: 5’-AGCCCTGTATCAACCCAGAA-3’ and reverse: 196 
5’-CAATGCCAACTCCACATAGC-3’; NCBI ID: 627) and for Glyceraldehyde Phosphate 197 
Dehydrogenase (GAPDH) were 5’-CCTCCTGCACCACCAACTGCTT-3’ and reverse 5’-198 
GAGGGGCCATCCACAGTCTTCT-3’; NCBI ID: 2597).  qRT-PCR reactions were carried out 199 
using a Eppendorf Mastercycler ep realplex2 real-time PCR System (Eppendorf, Canada).  200 
Relative mRNA expression was calculated using the delta Ct method (2-Δct) (Raue et al. 2006) 201 
and fold change from baseline was calculated using the delta-delta Ct method (2-ΔΔct) (Livak and 202 
Schmittgen 2001). A panel of housekeeping genes were run across all time-points to determine 203 
the most suitable housekeeping gene.  Glutaraldehyde phosphate dehydrogenase (GAPDH) 204 
mRNA was not different over time and thus chosen as the appropriate housekeeping gene.  Gene 205 
expression was normalized to the GAPDH.  mRNA values were expressed as either total mRNA 206 
expression (for between groups comparisons) and/or fold change from PRE for within group 207 
comparisons (mean ± SEM).  GAPDH was not different from PRE at any of the time points. 208 
Immunofluorescence: 209 
For Pax7 and MyoD the methods have been described in detail previously (McKay et al. 2012, 210 
McKay et al. 2010).  Briefly, 7 µm muscle cross-sections were stained with antibodies against 211 
Pax7 (neat; cell supernatant from cells obtained from the DSHB, USA); BDNF (1:100, 212 
ab108319, Abcam, USA); MyoD1 (Anti-MyoD1, Clone 5.8A, Dako Canada Inc., Canada); 213 
Laminin (1:1000, L8271, Sigma-Aldrich, Canada and Abcam ab11575, Abcam, USA); 214 
Myogenin (1:10; F5D clone cell supernatant from cells obtained from the DSHB, USA) and 215 
wheat germ agglutinin (WGA, 1:300, W11261) conjugated to AlexaFluor 647 (ThermoFisher 216 
Scientific, USA).  Secondary antibodies used were:  Pax7 (AlexaFluor 594, 1:500, Invitrogen, 217 
Molecular Probes Inc., USA); MyoD1, immunoglobulin biotinylated secondary antibody, 1:200, 218 
Dako Canada, Inc.; followed by a streptavidin-FITC fluorochrome, 1:100, Biosource. USA); 219 
BDNF (Dylight 488, 1:500, Thermo Scientific, Canada); Laminin (AlexaFluor 647, 1:500, or 220 
AlexaFluor 488, 1:200, Invitrogen, Molecular Probes Inc., USA); Myogenin (AlexaFluor 647, 221 
1:500, Invitrogen, Molecular Probes Inc., USA).   222 
Immunofluorescence methods were adapted from previously published methods from our 223 
lab (McKay et al. 2012, Joanisse et al. 2015).  Briefly, for co-immunofluorescent staining, 224 
sections were fixed with 2% paraformaldehyde (PFA, Sigma-Aldrich, Canada) for 10 min 225 
followed by several washes in PBS.  Sections were then incubated for 60 min in an optimized 226 
blocking solution containing, 2% bovine serum albumin (BSA; Sigma-Aldrich, Canada), 5% 227 
fetal bovine serum (FBS; Gibco, USA), 0.2% Triton-X 100 (Sigma-Aldrich, Canada), 0.1% 228 
sodium azide (Sigma-Aldrich, Canada), 5% goat serum (GS, Sigma-Aldrich, Canada).  229 
Following blocking, sections were incubated in the primary antibody cocktail (i.e. F5D and 230 
laminin diluted in 1% BSA) at 4°C overnight.  After several washes, sections were then 231 
incubated in the appropriate secondary antibodies.  To prevent any migration of secondary 232 
antibodies, sections were then re-fixed in 2% and re-blocked in 10% GS in 0.01% Triton-X 100.  233 
The sections were then incubated in the second primary antibody cocktail, followed by 234 
incubation in the appropriate secondary antibodies.  Sections were then washed with PBS 235 
followed by 4',6-diamidino-2-phenylindole (DAPI, 1:20000) (Sigma-Aldrich, Canada) for 236 
nuclear staining.  Staining was verified using the appropriate positive and negative controls to 237 
ensure specificity of staining.  Multiple experiments with multiple combinations of primaries 238 
with all secondaries were used to ensure no cross-reactivity between antigens and no unintended 239 
migration of secondaries.  Positive controls for Pax7 and MyoD were conducted previously on 240 
isolated murine myoblasts to ensure specificity.  Multiple secondary only controls were used for 241 
stains where multiple antigens were probed on the same slide.  Stained slides were viewed with 242 
the Nikon Eclipse Ti Microscope (Nikon Instruments, Inc., USA) and images were captured and 243 
analyzed using the Nikon NIS Elements AR 3.2 software (Nikon Instruments, Inc., USA).  For 244 
all analyses, the investigator was blinded to both the group and the time-points.  250 ± 15 muscle 245 
fibers were analyzed per section for each time point for each subject for all analyses.  Although 246 
previous work from (Mackey et al. 2009) demonstrated approximately 125 muscle fibers per 247 
sample was required to get an accurate SC quantification, we used 250 muscle fibers as a 248 
minimum because the sub-populations of SCs based on MyoD are more rare, we felt it necessary 249 
to obtain a more accurate count of these cells, especially Pax7-/MyoD+ -so-called differentiating 250 
cells.  Based on previous work with MyoD and other rare sub-populations (McKay et al. 2012, 251 
Joanisse et al. 2015), we feel quantification of 250 muscle fibers is sufficient for accurate 252 
analysis.  Immunofluorescent techniques for myogenin (F5D) were adapted from our previous 253 
published methods (Joanisse et al. 2015) and optimized to allow for co-immunostaining with 254 
BDNF.      255 
Blood Measures: 256 
Blood samples from the antecubital vein were taken immediately prior to the intervention and at 257 
6h, 24h, 72h, and 96h post.  Samples were collected in EDTA‐containing tubes and centrifuged 258 
at 1500 rpm for 10 min at 4°C. Samples were separated into 50 µL aliquots and stored at -80 °C 259 
for analysis at a later date.  Plasma samples were thawed on ice. Plasma BDNF was analyzed 260 
using a commercially available high sensitivity Quantikine Enzyme-Linked ImmunoSorbent 261 
Assay kit according to the manufacturer’s instructions (ab99978, Abcam, USA). 262 
Statistical Analysis: 263 
Statistical analysis was performed using SigmaStat 3.1.0 analysis software (Systat Software). 264 
One-way repeated measures ANOVA was performed with time (Pre, 6, 24, 72 and 96 h) as the 265 
main effect and Tukey HSD corrections were applied to account for multiple comparisons. In the 266 
case of comparisons of MyoD and Myogenin (figure 4e,f) main effects for group (i.e. MyoD vs. 267 
Myogenin) were assessed with paired t-tests.  The effect of time was already assessed (as above) 268 
and only the difference of group at each time point was tested.  All results are presented as 269 
means ± SEM. Statistical significance was accepted at P < 0.05. 270 
 271 
Results: 272 
The mixed muscle SC response to muscle damaging exercise: 273 
In the present study, we quantified ‘early differentiating’ SCs, or cells that were Pax7-/MyoD+. 274 
The ‘quiescent’ (Pax7+/MyoD-)cells and the ‘active’ (Pax7+/MyoD+)cells were quantified as part 275 
of a larger study examining the impact of capillarization and muscle repair (Nederveen et al. 276 
2018). At PRE, ‘quiescent’ cells represented 76% of the total SC pool, and ‘active’ cells 277 
represented 21% and ‘early differentiating’ cells represented 4% (Fig. 1a).  In the present study, 278 
we found that the proportion of cells negative for Pax7 and positive for MyoD was rare at PRE 279 
(0.3±0.1 Pax7-/MyoD+ cells/100MF) and increased from 4% of the total SC pool at PRE to 18% 280 
at 72h, peaking at 25% of the total SC pool at 96h, which represented an increase of 1137% in 281 
these cells from PRE (from PRE: 0.3±0.1 to 3.6±0.3 Pax7-/MyoD+ cells/100MF at 96h, p<0.05, 282 
Fig. 1b).  This cell population was very rare at baseline, representing only 1.1±0.2 cells in our 283 
250±15 myofiber muscle sections collected at the baseline time-point.  Although these cells are 284 
rare the quantification was consistent across the baseline time point and is similar to values 285 
previously reported (McKay et al. 2012, Joanisse et al. 2015).  Taken together, we found that our 286 
model of eccentric-contraction induced muscle damage was sufficient in stimulating an increase 287 
in ‘early differentiating’ Pax7-/MyoD+ cells (Fig. 1a), similarly to quiescent and active SCs, as 288 
previously published (27). Centrally located myonuclei (CLMN) were rare at baseline 289 
(0.29±0.08 CLMN per 100MF).  There was a significant increase in CLMN as early as 6h post-290 
intervention (158% increase, 0.75±0.19 CLMN/100MF, p<0.05).  The number for CLMN 291 
remained elevated throughout the post-intervention time-course peaking at 96h (214% increase 292 
from PRE, 0.91±0.18 CLMN/100MF, p<0.05,).     293 
 294 
Muscle SC activity and BDNF colocalization response to muscle damage: 295 
There is a large body of data to support the observation that BDNF co-localizes with satellite 296 
cells in animals; however, a paucity of data exists in humans (Mousavi and Jasmin 2006).  To 297 
test the hypothesis that BDNF is involved in SC regulation we first attempted to localize BDNF 298 
to human muscle SCs in muscle cross sections. We show here that BDNF co-localizes with Pax7 299 
(Figure 2).  To investigate the hypothesized association of BDNF with SC proliferation and 300 
differentiation we co-stained muscle cross-sections with Pax7, MyoD and BDNF.  At baseline 301 
(PRE), despite the majority of SCs being Pax7+/MyoD- (76% ‘quiescent’), none of these cells co-302 
stained positive for BDNF.  Throughout the post-intervention time-course we were unable to 303 
detect any Pax7+/MyoD- cells that stained positive for BDNF.   Figure 3b illustrates the time 304 
course of the co-localization of BDNF with ‘activated’ SCs (Pax7+/MyoD+/BDNF+ cells) as a 305 
proportion of the total Pax7+/MyoD+ cells.  At baseline 39±6% of Pax7+/MyoD+ cells co-306 
localized with BDNF (0.6±0.1 BDNF+/ Pax7+/MyoD+ cells/100MF).  This proportion increased 307 
significantly from PRE at 24h (71±3%, 4.1±0.2 BDNF+/ Pax7+/MyoD+ cells/100MF; P<0.05), 308 
72h (76±2 %, 5.6±0.1 BDNF+/ Pax7+/MyoD+ cells/100MF; P<0.05) and 96h (84±2 %, 5.5±0.2 309 
BDNF+/ Pax7+/MyoD+ cells/100MF; P<0.05) (fig. 3b). Interestingly, the co-localization with 310 
Pax7-/MyoD+ cells (early differentiation) increased 238% from PRE at 24h (13±5 % PRE to 311 
44±7 % 24h; 0.04±0.01 BDNF+/ Pax7-/MyoD+ cells/100MF at PRE to  0.50±0.07 BDNF+/ 312 
Pax7+/MyoD+ cells/100MF at 24h; P<0.05) and continued to increase at 72h (66±3 %;  313 
1.81±0.09 BDNF+/ Pax7+/MyoD+ cells/100MF; P<0.05) and 96h (68±4 %; 2.30±0.10 BDNF+/ 314 
Pax7+/MyoD+ cells/100MF; P<0.05) (fig. 3c).   315 
 316 
Myogenin and BNDF colocalization in response to muscle damage: 317 
In order to confirm the association of BDNF with SC differentiation we analyzed the co-318 
localization of BDNF with the myogenic regulatory factor myogenin.  The number of Myogenin+ 319 
cells increased 95% from PRE at 24h (PRE: 1.6±0.2 myogenin+ cells/100MF, 24h: 3.3±0.3 320 
myogenin+ cells/100MF, P<0.001 vs. PRE; P=0.002 24h vs. 6h, Fig. 4c) and remained elevated 321 
until 96h, p<0.05.  The proportion of BDNF+/Myogenin+ cells was 27±3% of total myogenin+ 322 
cells at PRE, increasing 76% at 24h (49±3% of total myogenin+ cells, p<0.001, Fig. 4d) and 323 
remained elevated at 96h (44±3% of total myogenin+ cells, p<0.002, Fig. 4d). 324 
Figure 4e and 4f demonstrate the temporal relation between the total number of myogenin+ cells 325 
per 100MF and the total number of MyoD+/Pax7- cells per 100MF (Fig 4e).  There are 326 
significantly more myogenin+ cells per 100MF at 24h compared to MyoD+/Pax7- cells (3.3±0.3 327 
myogenin+ cells/100MF vs. 1.1±0.1 MyoD+/Pax7- cells/100MF, p<0.05) compared to 328 
MyoD+/Pax7- cells.  The number of BDNF+/Myogenin+ cells were not different from the number 329 
of BDNF+/MyoD+/Pax7- cells until 72h (Fig 4f: 47.3±3.5% BDNF+/Myogenin+ cells vs. 330 
67.1±3.7% BDNF+/MyoD+/Pax7- cells at 72h, p<0.05).   331 
Whole-muscle and systemic response of BDNF to muscle damage: 332 
We observe a ~2.4-fold increase in BDNF mRNA expression as early as 6h post intervention 333 
(P<0.05, Fig 3a) that remained elevated throughout the post-intervention time-course (P<0.05, 334 
Fig 5a).  Similarly, BDNF protein in the plasma was detected at baseline and increased 26% at 335 
24h post intervention (Pre: 19.3±1.9 pg/mL to 26.3±3.0 pg/mL at 24h, p<0.05, Fig 5b).  Plasma 336 
BDNF returned to PRE levels by 72h (Fig. 5b).       337 
 338 
Discussion: 339 
Muscle SCs regulation is a complicated interplay between the systemic environment, the local 340 
microenvironment (skeletal muscle derived factors, etc.) and the direct interaction of the SC 341 
niche (skeletal muscle, capillaries, motor neurons and interstitium) (Snijders et al. 2015, Joanisse 342 
et al. 2017, Chakkalakal et al. 2012).  The neurotrophin BDNF has been identified as a potential 343 
regulator of SC function in animal models (Clow and Jasmin 2010).  It appears that BDNF acts 344 
via the receptor p75NTR, found on the cell surface of humans SCs (Colombo et al. 2011),  to 345 
influence SC proliferation and differentiation (Colombo et al. 2011, Colombo et al. 2013).   346 
Although the precise cellular signaling pathways responsible for this action remain to be 347 
elucidated, previous studies have demonstrated a potential role for BDNF in the regulation of 348 
myogenic stem cell proliferation and differentiation, this has never been described in vivo in 349 
humans.  In order to investigate whether BDNF is associated with the SC response in healthy 350 
humans we first set out to induce an expansion of the SC pool using an exercise-induced muscle 351 
damaging protocol that has been previously shown to cause a robust and reproducible SC 352 
response (McKay et al. 2010, Toth et al. 2011, Beaton, Tarnopolsky, and Phillips 2002).  In the 353 
present study, a significant increase in CLMN was noted from baseline.  Although the number of 354 
CLMN remained significantly elevated throughout the 96h post-intervention time-course, it is 355 
difficult to know if the CLMN represent injured myofibers per se or rather are nuclei undergoing 356 
karyolysis or normal myonuclear turnover.  In the present study we did not note enough CLMN 357 
to conduct co-immunostaining to attempt to identify lineage based on MRF expression, and these 358 
cells did not appear to stain with BDNF; however the numbers were very low and thus we were 359 
not able to interpret any possible trends.  Here we demonstrate a significant  increase in Pax7-360 
/MyoD+ cells per 100MF in mixed whole muscle that peaked 72h post myotrauma, which 361 
parallels the fiber-type specific SC response reported on the same subjects in a previous analysis, 362 
examining Pax7+/MyoD- and Pax7+/MyoD+ cells (Nederveen et al. 2018).  This is consistent 363 
with multiple studies from our lab and others using similar muscle damaging protocols  (Snijders 364 
et al. 2015, Nederveen et al. 2018).  It should be noted that this protocol evokes significant 365 
muscle injury compared to a normal workout and thus making generalizations to the response to 366 
resistance exercise may be difficult.  However, it is important to investigate a robust stimulus in 367 
order to stimulate enough of a response to be quantifiable based on current techniques, as such 368 
the use of 300 eccentric contractions is an effective and standardized model for our human trial.  369 
To further characterize the SC response to muscle injury, we identified SCs based on 370 
MyoD and Pax7 expression.  It is generally accepted that SCs in the quiescent state express some 371 
level of Pax7 in post-natal muscle tissue and upon activation, upregulate Myf5 and MyoD 372 
(Zammit, Partridge, and Yablonka-Reuveni 2006, Lepper, Partridge, and Fan 2011).  373 
Furthermore, as these cells begin to differentiate they downregulate Pax7 and a sub-set of cells 374 
down regulate MyoD and remain Pax7 positive, returning to a quiescent state to repopulate the 375 
SC pool (Zammit et al. 2004, Zammit, Partridge, and Yablonka-Reuveni 2006). Based on this 376 
principle we investigated the sub-populations of SCs that were Pax7+/MyoD- (so called 377 
‘quiescent’ SCs), Pax7+/MyoD+ cells (‘active / proliferating’), and Pax7-/MyoD+ cells 378 
(‘differentiating’ or preparing to differentiate).  Similar to previous studies (McKay et al. 2012, 379 
Joanisse et al. 2015, Nederveen et al. 2018), we found the majority of SCs were MyoD- at 380 
baseline with relatively few Pax7-/MyoD+ cells (<4% of the total SC pool).  These ‘early 381 
differentiating’ SC (Pax7-/MyoD+) increased 1137% peaking at 96h.  Importantly, the 382 
differential response of these three sub-populations of SCs allow for the quantification of BDNF 383 
in these cells at the different time points following muscle damage.  384 
In order to help elucidate the relationship of BDNF with the SC response, we first set out 385 
to confirm the localization of BDNF with Pax7+ SCs using immunofluorescent techniques (fig. 386 
2).  Here we identified both Pax7+/BDNF+ cells and Pax7+/BDNF- cells in the same muscle 387 
sections (fig. 2).  Previous studies in murine muscle have demonstrated BDNF co-localized with 388 
SCs in vitro and in vivo (Mousavi and Jasmin 2006, Clow and Jasmin 2010, Miura et al. 2012).  389 
To date, only one other study has attempted to localize BDNF with human SCs (Colombo et al. 390 
2013).  In that study, SCs were analyzed in muscle cross-sections using immunohistochemical 391 
detection and myoblasts were also isolated based on CD56/NCAM expression for in vitro 392 
experiments (Colombo et al. 2013).  They not only localized BDNF protein to the SCs using co-393 
immunohistochemical detection with BDNF and NCAM, but they also used in situ hybridization 394 
to localize BDNF to SCs in cross-section (Colombo et al. 2013) further lending strength to the 395 
potential role of BDNF in SC regulation.  In that study, in the basal state, >80% of SCs from 396 
patients with inflammatory myopathies were positive for BDNF (BDNF+/NCAM+).  This is in 397 
contrast to data from the present study, where in young healthy controls approximately 75% of 398 
SCs were negative for MyoD (i.e. SC remain in quiescent state) and were also negative for 399 
BDNF.  In that study, muscle biopsies were obtained from 17 patients with a known diagnosis of 400 
inflammatory myopathy (polymyositis, dermatomyositis, or inclusion body myositis) with a 401 
mean age of 65y with 10 patients being male and 7 being female. Taken together, it is difficult to 402 
make direct comparison between that study and our data.  It is important to note that BDNF 403 
protein is also expressed by the muscle fiber and that BDNF expression increases with exercise 404 
(Matthews et al. 2009), but the exact functions of BDNF within muscle fibers is not clear.  There 405 
may be autocrine/paracrine cross-talk between the fiber and SCs, however this is yet to be 406 
established in humans.  407 
    In the present study, the percentage of SCs co-staining for BDNF increased the most in 408 
cells expressing MyoD and importantly, was not detected in cells expressing only Pax7 409 
(Pax7+/MyoD-).  Thus, data from the three sub-populations of SCs (based on Pax7 and MyoD 410 
co-staining) across the 96h time course may indicate that BDNF expression is involved in the 411 
later stages of the myogenic program.  Our findings are strengthened by the work of Colombo 412 
and colleagues (2013) who also demonstrated using siRNA against BDNF, that myoblast 413 
differentiation was impaired when BDNF levels were either silenced or blocked with a BDNF 414 
antibody in cell culture (Colombo et al. 2013).  Although data from the present study and 415 
Colombo et al. (2013) suggest there is an association with BDNF and SC differentiation, and that 416 
differentiation is impaired when BDNF is absent (Colombo et al. 2013), data from animal studies 417 
suggest that BDNF is associated with SC proliferation and high levels of BDNF impair 418 
myogenic differentiation (Clow and Jasmin 2010, Miura et al. 2012).  The difference in the exact 419 
role of BDNF with regards to regulation of SC proliferation or differentiation between humans 420 
and mice may be due to significant differences in study design and possibly due to species 421 
differences in signaling.  In addition, the lack studies published in this area is also a key factor 422 
which must be considered in explaining discrepancies between published data. 423 
   424 
To further determine the association of BDNF with SC differentiation, we investigated 425 
the co-expression of BDNF with the myogenic differentiation factor myogenin.  Fig. 4 illustrates 426 
that an increase in myogenin+ cells is seen as early as 24h following myotrauma and that these 427 
cells remain elevated at 96h.  Furthermore, as the number of these cells increases, the proportion 428 
co-expressing BDNF increased from ~27% at baseline to ~49% at 24h, and remained elevated at 429 
96h.  Therefore, these data suggest there is an association of BDNF with SC differentiation.   430 
When we look at both the response of myogenin+ cells with BDNF and MyoD+/Pax7- cells with 431 
BDNF together (Fig. 4e, f) we see that the total proportion of these cell populations increase with 432 
time and that BDNF+/MyoD+/Pax7- cells are increasing at a greater rate and reach a higher 433 
proportion of total Myogenin+ cells or total MyoD+/Pax7- cells (Fig. 4f).  This may represent a 434 
critical importance of BDNF with late proliferation or early differentiation/transition to 435 
differentiation.    A limitation of this interpretation is that it is unclear whether myogenin+ cells 436 
beneath the basal lamina represent SCs that have progressed towards myogenic differentiation or 437 
are proliferating cells that are up-regulating myogenin in preparation for differentiation or 438 
alternately, are cells that have fully differentiated and fused with the myofiber. Due to technical 439 
constraints of using multiple mouse monoclonal antibodies we are currently unable to co-stain 440 
myogenin with Pax7 or directly with MyoD.  In addition, interpreting the precise mechanisms 441 
involved in the in vitro human model is limited by the amount of muscle we can extract and thus 442 
the relatively low populations of these cells.  The fact we are able to consistently quantify 443 
population expansion in the model does lend credence to the biological significance of the 444 
interactions of signaling molecules examined here.  In addition, multiple labelling of 445 
histopathological sections is difficult, especially with rare cell types in whole tissue sections.  446 
The use of flow cytometry or fluorescence activated cell sorting may further enable more presice 447 
quantification of cell populations with respect to activation status and expression of other 448 
proteins such as BDNF.  Unfortunately, at the present time the isolation procedure for this 449 
technique still requires a lot of tissue, which is a challenge for human studies where tissue is 450 
sparce.  At present our lab is working on optimizing this technique for future studies.  451 
In the present study, circulating BDNF increased from basal levels approximately 26% 452 
by 24h and returned to baseline by 72h following unilateral eccentric contractions.  In skeletal 453 
muscle, whole-muscle BDNF mRNA was increased as early as 6h following muscle damage and 454 
remained elevated throughout the 96h post-intervention time-course.  The differential time-455 
course of circulating BDNF compared to whole muscle transcripts suggests that it is unlikely that 456 
muscle accounts solely for the transient increase in circulating BDNF.  Furthermore, the 457 
differential timeline of BDNF within the SC compartment suggests that BDNF may have 458 
differential effects based on the temporal and spatial factors.  Exercise is known to induce an 459 
increase in circulating BDNF (Dinoff et al. 2017); however, it is unclear if the source of BDNF 460 
is neural tissue, skeletal muscle, other peripheral tissues (such as circulating cells or other 461 
organs) or if it is combination of some or all of these (Dinoff et al. 2017, Colombo et al. 2013).  462 
Recent data from human skeletal muscle and human primary myoblasts demonstrated that the 463 
skeletal muscle, the SCs and local inflammatory cells all produce BDNF in regenerating 464 
myofibers, suggesting a key role for autocrine/paracrine and immune effects of BDNF in the 465 
local SC microenvironment (i.e., the niche) on myogenesis (Colombo et al. 2013).  However, the 466 
exact mechanisms responsible for the local and systemic increase in BDNF remain uncertain. 467 
Another limitation of this relation is the theoretical cross-reactivity of the BDNF antibody used 468 
vs. the specificity of the primer sequences for RNA analysis.  Many commercially available 469 
BDNF antibodies may cross-react with other neurotrophins such as NGF4, neurotrophin 3 and 4.  470 
Unfortunately, based on similarities in protein structures between these compounds we cannot 471 
say for certain that 100% of the BDNF antibody is bound solely to BDNF       472 
BDNF signaling between skeletal muscle and SCs appears to be an important and 473 
understudied area of SC biology (Colombo et al. 2013, Clow and Jasmin 2010).  Several basic 474 
science studies in animals and humans have begun to classify a role for BDNF in SC 475 
proliferation and differentiation (Clow and Jasmin 2010, Miura et al. 2012, Colombo et al. 476 
2013).  Importantly, BDNF has been shown here to be associated with SC proliferation and 477 
differentiation in human muscle in vivo, following exercise-induced muscle damage, with BDNF 478 
increasing in SCs during the later stages of proliferation and early differentiation.  This study 479 
provides key evidence that BDNF is associated with the robust SC response to physiological 480 
muscle damage in healthy young adults.   481 
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Figure Legend: 612 
Figure 1: The Satellite cell (SC) response to acute exercise-induced muscle damage. 613 
 The SC-specific MyoD response – (1a) Graphic representation of the proportion of 614 
Pax7+/MyoD- (‘quiescent’ – black bars); Pax7+/MyoD+ (‘active’ – white bars); Pax7-/MyoD+ 615 
(‘early differentiation’ – grey bars) cells as a proportion of the total SC population (per 100 616 
myofibers) over the time-course.  (1b) Line graph of this response demonstrating the individual 617 
changes in Pax7-/MyoD+ cells per 100 myofibers (‘early differentiation’) *p<0.05 vs. Pre and 6h. 618 
†p<0.05 vs. Pre, 6h, and 24h. Note: All three groups are significantly different from each other at 619 
each time point (group main effect p<0.05). 620 
 621 
Figure 2: Immunohistochemical detection of BDNF within the SC pool. 622 
(2a) A representative muscle cross-section demonstrating a BDNF negative SC. The arrow 623 
denotes a BDNF negative (green), Pax7 positive (red), cell (nuclei, DAPI) beneath the basal 624 
lamina (Laminin, purple). 625 
(2b) A representative muscle cross section demonstrating a BDNF positive SC. The arrow 626 
denotes a BDNF positive (green), Pax7 positive (red), cell (nuclei, DAPI) beneath the basal 627 
lamina (Laminin, purple). 628 
 629 
Figure 3: The response of BDNF with the subpopulations of SCs based on MyoD and Pax7 co-630 
expression to exercise-induced muscle damage. 631 
(3a) A representative muscle cross-section stained with Pax7 (green), MyoD (Red), BDNF 632 
(purple) and DAPI (blue).  The upper left box is expanded below and illustrates a Pax7-/MyoD+ 633 
cells that is positive for BDNF.  The box in the lower right corner is expanded to the right and 634 
illustrates a Pax7+/MyoD- cell that is BDNF negative.  635 
(3b) A graphic representation of the quantification of the proportion of Pax7+/MyoD+ cells that 636 
are also positive for BDNF (expressed as a percentage of total Pax7+ /MyoD+/ cells).  *p<0.05 637 
vs. Pre. †p<0.05 vs. 6h.  638 
(3c) A graphic representation of the quantification of the proportion of Pax7-MyoD+ cells that are 639 
also positive for BDNF (expressed as a percentage of total Pax7- /MyoD+ cells).  *p<0.05 vs. 640 
Pre. †p<0.05 vs. 6h. 641 
 642 
Figure 4: The response of myogenin and the co-expression of myogenin and BDNF to exercise-643 
induced muscle damage.  644 
(4a) A representative muscle cross-section stained with BDNF (green), myogenin (Red), laminin 645 
(orange) and DAPI (blue).  The arrow denotes a myogenin positive cell under the basal lamina 646 
negative for BDNF. 647 
(4b) A representative muscle cross-section stained with BDNF (green), myogenin (Red), laminin 648 
(orange) and DAPI (blue).  The arrow denotes a myogenin positive cell under the basal lamina 649 
that is positive for BDNF. 650 
(4c) A graphic representation of the quantification of the response of myogenin positive cells per 651 
100 myofibers.  *p<0.05 vs. Pre. †p<0.05 vs. 6h. 652 
(4d) A graphic representation of the quantification of the proportion of myogenin positive cells 653 
that are also positive for BDNF (expressed as a percentage of total myogenin positive cells).  654 
*p<0.05 vs. Pre. 655 
(4e) A graphic representation of relationship between the total Myogenin positive cell population 656 
with the MyoD+/Pax7- cell population.  Both populations increase in the later part of the recovery 657 
period following exercise-induced muscle damage. *p<0.05 vs. Pax7- /MyoD+ (main effect of 658 
group per time point).  Note: effect of time for each group is reported in the previous graphs.       659 
(4f) A graphic representation of the Myogenin positive cell population that is BDNF+ with the 660 
Pax7-/MyoD+ cell population that is BDNF+.  *p<0.05 vs. Myogenin (main effect of group per 661 
time point).  Note: effect of time for each group is reported in the previous graphs.       662 
 663 
 664 
Figure 5: The whole-muscle and systemic BNDF response to exercise-induced muscle damage. 665 
(5a) BDNF mRNA from whole-muscle expressed as fold change from Pre.  *p<0.05 from Pre 666 
(5b) Plasma BDNF concentration. *p<0.05 from Pre 667 
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